Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the world health organization quality of life BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients

M. de Mol, S. Visser, J.G.J.V. Aerts, P. Lodder, J. de Vries, B.L. den Oudsten

Research output: Contribution to journalArticleScientificpeer-review

14 Downloads (Pure)

Abstract

Background
To determine the psychometric properties and minimal clinically important differences (MCIDs) of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) in advanced stage lung cancer patients.
Methods
Patients (n = 153) completed the WHOQOL-BREF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Confirmatory factor analysis (CFA) was performed and reliability and construct validity determined. MCIDs were estimated with two distribution-based methods (0.5 standard deviation (SD) and 1 standard error of measurement (1 SEM)).
Results
CFA confirmed WHOQOL-BREF domain structure. All domains demonstrated good internal consistency (α > 0.70), except Social Relationships (α = 0.57). Nineteen of the 24 WHOQOL-BREF items had correlations of ≥ 0.40 with their intended domain. Four items had higher correlations with a domain other than their intended domain. Moderate to strong correlations were observed for corresponding domains of the two questionnaires, except for the social domains (r = 0.07). For 0.5 SD, MCIDs ranged from 0.88 to 1.55, and for 1 SEM MCIDs ranged from 1.76 to 2.72.
Conclusions
The WHOQOL-BREF has satisfactory psychometric properties in patients with advanced stage lung cancer, whereas the observed MCIDs provide a method for interpretation of scores.
Original languageEnglish
Article number1173
Number of pages12
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Mesothelioma
Minimal Clinically Important Difference
Surveys and Questionnaires
Statistical Factor Analysis

Keywords

  • BEVACIZUMAB
  • CHEMOTHERAPY
  • EORTC QLQ-C30
  • FACT-G
  • INSTRUMENT
  • INTRAINDIVIDUAL CHANGES
  • Lung cancer
  • METAANALYSIS
  • Minimal clinically important difference
  • NEWLY-DIAGNOSED PATIENTS
  • OF-LIFE
  • Quality of life
  • Reliability
  • SUPPORTIVE CARE
  • Validity
  • World Health Organization quality of life-BREF

Cite this

@article{aad3b14f2d054242927931e822ab9978,
title = "Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the world health organization quality of life BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients",
abstract = "BackgroundTo determine the psychometric properties and minimal clinically important differences (MCIDs) of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) in advanced stage lung cancer patients.MethodsPatients (n = 153) completed the WHOQOL-BREF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Confirmatory factor analysis (CFA) was performed and reliability and construct validity determined. MCIDs were estimated with two distribution-based methods (0.5 standard deviation (SD) and 1 standard error of measurement (1 SEM)).ResultsCFA confirmed WHOQOL-BREF domain structure. All domains demonstrated good internal consistency (α > 0.70), except Social Relationships (α = 0.57). Nineteen of the 24 WHOQOL-BREF items had correlations of ≥ 0.40 with their intended domain. Four items had higher correlations with a domain other than their intended domain. Moderate to strong correlations were observed for corresponding domains of the two questionnaires, except for the social domains (r = 0.07). For 0.5 SD, MCIDs ranged from 0.88 to 1.55, and for 1 SEM MCIDs ranged from 1.76 to 2.72.ConclusionsThe WHOQOL-BREF has satisfactory psychometric properties in patients with advanced stage lung cancer, whereas the observed MCIDs provide a method for interpretation of scores.",
keywords = "BEVACIZUMAB, CHEMOTHERAPY, EORTC QLQ-C30, FACT-G, INSTRUMENT, INTRAINDIVIDUAL CHANGES, Lung cancer, METAANALYSIS, Minimal clinically important difference, NEWLY-DIAGNOSED PATIENTS, OF-LIFE, Quality of life, Reliability, SUPPORTIVE CARE, Validity, World Health Organization quality of life-BREF",
author = "{de Mol}, M. and S. Visser and J.G.J.V. Aerts and P. Lodder and {de Vries}, J. and {den Oudsten}, B.L.",
year = "2018",
doi = "10.1186/s12885-018-4793-8",
language = "English",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the world health organization quality of life BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients

AU - de Mol, M.

AU - Visser, S.

AU - Aerts, J.G.J.V.

AU - Lodder, P.

AU - de Vries, J.

AU - den Oudsten, B.L.

PY - 2018

Y1 - 2018

N2 - BackgroundTo determine the psychometric properties and minimal clinically important differences (MCIDs) of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) in advanced stage lung cancer patients.MethodsPatients (n = 153) completed the WHOQOL-BREF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Confirmatory factor analysis (CFA) was performed and reliability and construct validity determined. MCIDs were estimated with two distribution-based methods (0.5 standard deviation (SD) and 1 standard error of measurement (1 SEM)).ResultsCFA confirmed WHOQOL-BREF domain structure. All domains demonstrated good internal consistency (α > 0.70), except Social Relationships (α = 0.57). Nineteen of the 24 WHOQOL-BREF items had correlations of ≥ 0.40 with their intended domain. Four items had higher correlations with a domain other than their intended domain. Moderate to strong correlations were observed for corresponding domains of the two questionnaires, except for the social domains (r = 0.07). For 0.5 SD, MCIDs ranged from 0.88 to 1.55, and for 1 SEM MCIDs ranged from 1.76 to 2.72.ConclusionsThe WHOQOL-BREF has satisfactory psychometric properties in patients with advanced stage lung cancer, whereas the observed MCIDs provide a method for interpretation of scores.

AB - BackgroundTo determine the psychometric properties and minimal clinically important differences (MCIDs) of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) in advanced stage lung cancer patients.MethodsPatients (n = 153) completed the WHOQOL-BREF and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Confirmatory factor analysis (CFA) was performed and reliability and construct validity determined. MCIDs were estimated with two distribution-based methods (0.5 standard deviation (SD) and 1 standard error of measurement (1 SEM)).ResultsCFA confirmed WHOQOL-BREF domain structure. All domains demonstrated good internal consistency (α > 0.70), except Social Relationships (α = 0.57). Nineteen of the 24 WHOQOL-BREF items had correlations of ≥ 0.40 with their intended domain. Four items had higher correlations with a domain other than their intended domain. Moderate to strong correlations were observed for corresponding domains of the two questionnaires, except for the social domains (r = 0.07). For 0.5 SD, MCIDs ranged from 0.88 to 1.55, and for 1 SEM MCIDs ranged from 1.76 to 2.72.ConclusionsThe WHOQOL-BREF has satisfactory psychometric properties in patients with advanced stage lung cancer, whereas the observed MCIDs provide a method for interpretation of scores.

KW - BEVACIZUMAB

KW - CHEMOTHERAPY

KW - EORTC QLQ-C30

KW - FACT-G

KW - INSTRUMENT

KW - INTRAINDIVIDUAL CHANGES

KW - Lung cancer

KW - METAANALYSIS

KW - Minimal clinically important difference

KW - NEWLY-DIAGNOSED PATIENTS

KW - OF-LIFE

KW - Quality of life

KW - Reliability

KW - SUPPORTIVE CARE

KW - Validity

KW - World Health Organization quality of life-BREF

U2 - 10.1186/s12885-018-4793-8

DO - 10.1186/s12885-018-4793-8

M3 - Article

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 1173

ER -